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Key message points 
 
 There has been litigation in relation to the three types of harm 
associated with contraceptive implants: non-insertion, deep insertion 
and nerve injury 
 Recommendations for safe clinical practice can be derived from 
analysis of legal cases and published case reports  
 Nerve injury has invariably been caused by clinicians without upper 
limb surgical skills attempting difficult removals 
 The launch of the updated single-rod implant (Nexplanon®) may hold 
the best possibility for harm reduction 
 Litigation in relation to side effects can lead to the withdrawal of safe 
and effective contraceptive products, so reducing choice for women 
 
 
Introduction 
 
Litigation can be seen as a reflection of medical error and harm to patients. 
Studying litigation may reveal trends from which lessons can be learned, 
leading to  improvements in patient safety1. The threat of litigation may be of 
some value in increasing investment in safety2. An alternative to costly 
litigation is a no-fault compensation system, as was established in New 
Zealand in 19743. In this system doctors of good standing who generally 
perform well are not punished by being subjected to an adversarial legal 
system. Members of the public who are harmed by errors receive fair, timely 
compensation. However, such a system may result in less accountability3. 
 
This article aims to review some legal aspects of contraceptive implants. 
Three types of incident repeatedly feature in legal cases in a range of 
countries: non-insertion, deep insertion and nerve injury.  
 
 
Background 
 
After research on contraceptive implants from 1966 onwards, a six-capsule 
delivery system with a lifespan of five years was ready for clinical studies by 
1974. Multinational phase III trials of this system called Norplant  followed. 
The first country to receive marketing authorisation was Finland in 1983. By 
1990, more than 0.5 million women had used Norplant  in 17 countries 
where it had marketing authorisation and in a further 29 countries where pre-
introductory trials had taken place. 
 
In the UK the manufacturer of Norplant , Roussel, devised a cascade 
programme: eight key clinicians went to Jakarta, Indonesia, for a week in 
April 1993 to practise insertion, removal and counselling techniques. On their 
return, these eight key instructors trained key health professionals in 35 
training centres – this second tier then provided training in their regions for 
GPs, family planning doctors and gynaecologists. The product was launched 
in the UK in October 1993. Within 14 months, around 3,600 doctors had 
completed the practical training for insertion. Many of these doctors were GPs 
without family planning training. After an initial surge of enthusiasm, many 
did not persist with the work and in particular did not train to do removals. 
There was also a reluctance by many GPs to do implant procedures due to 
lack of an item of service fee4. 
 
In 1995, a UK group action was mounted against the manufacturer of 
Norplant . A firm of solicitors in Nottingham coordinated cases from 34 
different firms. It was the first attempt to bring a case of a prescription only 
medicine as an allegedly defective product under the Consumer Protection Act 
19875. There was an initial allegation that the product was introduced hastily 
with a substandard training programme, but expert evidence did not support 
this. The main claim, by 275 women, was for a range of possible 
levonorgestrel-related side effects and difficulties with removal. The allegation 
was that the product information did not fairly represent the severity of the 
adverse effects associated with the product. The individual claims for 
damages were small. Legal aid had been granted for 189 of these women. 
The case collapsed in 1999 when the Legal Aid Board, as it then was, 
withdrew funding, having decided that the chances of success did not justify 
the high cost of a trial6. The remainder of the women, who were self-funding, 
decided to withdraw at this point. Exchange of expert evidence had revealed 
that the effects of the product were within the predicted range and fairly 
summarised, so that there was no defect in the product. 
 
Two months later, the manufacturer decided to discontinue the sale of 
Norplant  in the UK on commercial grounds. The number of women using 
the product had reached only 55,000 (among 6 million users worldwide), the 
manufacturer having spent £3 million on doctor training alone.  A „boom and 
bust‟ phenomenon7 which had been seen in the USA, characterised by a 
degree of overpromotion initially followed by adverse reports in the media8 
and litigation, also occurred to some extent in the UK.  
 
However, the situation was different in the USA.  In the mid-1990s, when one 
million women were using Norplant 9, 36,000 women commenced a class 
action against the manufacturer. Allegations of harm fell into three broad 
categories9:  
 removal difficulties 
 possible levonorgestrel side effects  
 silastic-related claims including autoimmune disorders alleged to be 
related to the silicone elastomer tubing 
 
Despite the threatened litigation, Wyeth-Ayerst Laboratories decided to 
continue marketing the product. Even with aggressive recruitment by 
personal injury lawyers, only approximately five percent of all Norplant  
users joined lawsuits, and the courts denied class action status for the 
plaintiffs10. The vast majority of the 14,000 US cases were dismissed, and 
eventually only a small number were settled out of court for an average of 
$1,400 each. 
 
In the UK Implanon , a single-rod implant containing etonogestrel, was 
launched by Organon Laboratories in a more measured fashion than 
Norplant  had been. Implanon  has a three-year lifespan. It is a semi-rigid 
rod, making it more robust and quicker and easier to insert and remove  than 
Norplant . Unlike Norplant , it is amenable to the „pop-out‟ removal 
technique. The launch in 1999 was less of a challenge than that of Norplant  
because there was already a clinical workforce in place with experience of 
implant techniques. Initial training was confined to contraception specialists.  
 
The Implanon  applicator has recently been redesigned and the product 
relaunched as Nexplanon  by the current manufacturer, MSD, with a view to 
reducing the risks of non-insertion and deep insertion11.   Also, the new rod is 
radio-opaque to aid imaging of non-palpable implants12.   
 
The following three types of harm associated with Implanon  are based on 
global experience over 11 years with the original applicator design. 
 
 
 
Non-insertion 
 
Clinicians who act as expert witnesses in relation to legal cases have seen a 
substantial number of cases of litigation on account of non-insertion of 
Implanon , usually presenting with an unexpected pregnancy: the implant 
cannot be palpated, is not seen on ultrasound scan and etonogestrel is 
undetectable in serum. Non-insertion with pre-loaded Implanon , 
unrecognised at the time, was not reported in the pre-launch trials13. Clinical 
trials conducted during the development of Implanon  covered 4103 woman 
years and reported no pregnancies14. True method failures might have been 
predicted after more extensive use, but not failure to have placed a device in 
the arm at the end of the insertion procedure. 
 
In Australia, after national post-marketing surveillance picked up 84 cases of 
non-insertion, a risk management process was invoked15. In France, 30 cases 
of non-insertion were reported to regional pharmacovigilance centres16. Cases 
of non-insertion have been reported in the British literature too17;18. 
Spontaneous reporting to the Medicines and Healthcare products Regulatory 
Agency (MHRA)19 recorded 535 unintended pregnancies by 27 May 2010, but 
the proportion of these due to non-insertion is not known. 
 
Implanon  was launched in the Netherlands in 1999.  In 2002, a class action 
against Organon and 13 general practitioners was brought by 15 Dutch 
women who had become pregnant following non-insertion. Ten of these 
women continued their pregnancies and delivered, four had abortions and 
one miscarried.  At the trial in 2005, Organon and/or the doctors were found 
liable for the unintended pregnancies.  The judge concluded that both the 
company and the doctors should pay damages unless either could bring 
further evidence. In 2007, at appeal with new evidence presented, the 
decision was reversed and the burden of proof transferred to the women20. 
The women were told that in order to succeed in court they would have to 
prove that their doctor failed to check: a) that the implant was present in the 
needle, b) that it was no longer in the needle after the procedure and c) that 
it could be palpated in the arm after the procedure. This judgment effectively 
ended the class action. However, individual claims had been settled out of 
court in favour of Dutch claimants. In Britain, the amount of damages paid 
out for wrongful conception is small because of the limiting effect of the 
McFarlane case. In McFarlane, it was held by a majority of Law Lords that the 
McFarlanes could recover damages for the wife‟s pain and distress in 
pregnancy and labour following the husband‟s failed vasectomy, but not for 
the cost of raising their daughter21. However, in the Netherlands, damages 
can include the cost of the upbringing of the child born.  Award of this higher 
level of damages has also been reported in Australia22. 
 
In an attempt to reduce the chance of a non-insertion, the company 
reinforced pre-existing advice in a letter to clinicians dated June 2001, 
stressing that: 
 the presence of the implant must be visually verified before insertion is 
performed 
 the introducer should be held with the needle upwards at all times 
between removing the needle shield and the insertion 
 the obturator should be retracted to check that the needle is empty 
after insertion 
 the implant should be carefully palpated in the arm after insertion 
 
The manufacturer also modified the end of the obturator in 2004; it added a 
groove in its tip so that there can be no confusion with the appearance of an 
implant still in the needle after insertion. However, this does not confirm that 
the implant has been inserted successfully. 
 
Despite revised guidance and publication of case reports of this problem, 
sporadic cases of non-insertion have continued to be seen in clinical and legal 
practice.  
 
 
Deep insertions 
 
Contraceptive implants should be inserted into the subdermal plane. The 
problem of difficult removals due to deep insertion was first seen with 
Norplant ; it was found that 1% of removals were complicated because the 
implant was ‟embedded‟23. Deep insertion is thought to be associated with the 
insertion technique rather than migration of a properly inserted implant18;24;25. 
It has been suggested that with Implanon  the implant may be pushed out 
of the applicator, rather than using the correct technique of withdrawing the 
outer casing, keeping the obturator fixed; the implant may then take the path 
of least resistance24. In some cases, the proximal end of the implant is seen 
to be deeper than the distal end, suggesting a downward slant of the 
applicator at the time of insertion18.  
 
Deep insertion may be more likely to occur in thin women with scant 
subcutaneous tissue25.  Weight gain subsequent to insertion may make an 
implant less easy to palpate and therefore more difficult to remove26. 
 
It is not thought that a rod can migrate significantly in the arm unless it is 
placed subcutaneously27. Migration of up to 5cm has been reported but is 
rare28. It seems unlikely that implants can penetrate fascia spontaneously. 
However, a degree of migration has been reported when Implanon  implants 
have been inserted into the wound immediately after removal of 
Norplant 25;29.   
 
If an implant cannot be palpated when removal is being considered, imaging 
may assist.  An ultrasound or MRI scan will usually show the position of the 
implant30. Fluoroscopy has also been used by interventional radiologists31. 
The original version of Implanon  does not show up reliably on X-rays or CT 
scans.  Since 2003, there have been several case reports and case series of 
impalpable Implanons  and suggestions as to how best to retrieve these 
18;24;29;32. The consensus is that there must be accurate localisation of the 
implant using a high resolution linear array ultrasound transducer before an 
incision is made25. 
 The concept of specialist centres for predictably difficult removals had evolved 
in the Norplant  era33. UK recommended practice was further reinforced by 
US experience showing that real-time ultrasound guidance was a very useful 
way of localising Norplant  capsules34 and that this was possible in a non-
hospital setting. With Implanon , further experience has been gained and the 
number of specialist centres has expanded35. MSD now provides a training 
course for expert removers in the localisation of deep Implanons  and the 
identification of adjacent neurovascular structures; this course was developed 
in order to minimise the risk of injury to these structures. The course 
comprises training on the anatomy of the arm, on the use of ultrasound for 
imaging the upper arm and on surgical techniques for complex implant 
removal (MSD: personal communication, 29 July 2010). 
 
The most common abnormal positioning of implants is deep in subcutaneous 
fat. Placement overlying or within the biceps muscle is the next most common 
abnormal positioning18;36. Placement in the triceps muscle has also been 
described25. Deep implants may be located near or within the neurovascular 
bundle37;38. 
 
There have been many cases of deep placement of implants, some of which 
have resulted in litigation. The cases sometimes involve two or more attempts 
at removal. In some cases regional experts fail to remove the implant. In 
such cases, the women are usually referred to a surgeon who may be a 
general surgeon, a plastic surgeon or an orthopaedic surgeon. Generally the 
surgeon will do the removal under general anaesthesia with a fairly generous 
longitudinal incision. With a few exceptions, surgeons appear to have little 
difficulty finding and removing an implant under these conditions.  As far as 
the author is aware, injury to neurovascular structures has not been seen 
when removal is performed by a surgeon.  Legal cases of failed removals with 
subsequent surgical removal under general anaesthesia have been settled out 
of court in Britain. For example, in 2005, a claimant was awarded £8,500 in 
damages to be paid by Sefton Primary Care Trust39. In France there have 
been similar experiences, with medical defence insurance covering the 
costs38. 
 
As a result of the above considerations, a widely adopted protocol is that if an 
implant cannot be palpated easily, a more experienced member of the local 
team should attempt removal. Implants that are completely impalpable should 
be referred to a regional centre where removal of non-palpable implants using 
techniques developed by leading experts 40 is almost always successful. 
Nevertheless, following complex removal procedures there is potential for 
neurovascular injury, infection and scar or keloid formation.  Regional centres 
that demonstrate that implants are close to vital structures may decide to 
refer onward to surgeons or interventional radiologists40. 
 
 
Nerve injury 
 
The positioning of implants in the body had been given a considerable 
amount of thought before Norplant  was launched. Sites such as the 
abdomen are not favoured for non-biodegradable implants as migration is 
prone to occur. The arm is preferred because of the minimal thickness of 
subcutaneous tissue; the disadvantage is that vital structures are nearer the 
surface. The Summer 2000 issue of the Implanon Newsletter, produced by 
Organon for clinicians trained to insert Implanon , reiterated the rationale for 
the site of insertion. Placement in the groove was recommended to limit the 
chance of migration, but with a warning of the presence of the neurovascular 
bundle just beneath the fascia. A warning was also given of the not 
uncommon variation in the position and branching of the brachial artery. 
Careful inspection and palpation of the arm prior to insertion was advised. 
 
The recommended site for both Norplant  and Implanon  used to be 6 - 8 
cm above the elbow crease, in the groove between biceps and triceps 
muscles. The neurovascular bundle, comprising the brachial artery, basilic 
vein, median nerve, ulnar nerve and medial cutaneous nerve of the forearm is 
situated a few millimetres deep to the fascia at this point (Figure 1). For 
reasons that are not clear, damage to the neurovascular bundle is usually 
confined to nerves. Vascular injury has been reported41, but is rare. 
 
In this section of the article, three anonymised examples of legal cases are 
used from the author‟s experience as an expert witness. 
 
More than a decade ago a case of ulnar nerve palsy in association with 
insertion of Norplant 42 was reported. There is one other report relating to 
injury to a nerve at the time of Norplant  insertion.  This involved sensory 
loss in the distribution of the medial cutaneous nerve of the forearm43. In 
general, however, nerve injury occurs in association with implant removal. 
 
In 1995, a paper from the USA highlighted the possibility of damaging nerves 
during difficult Norplant  removals and related this to the recommended 
insertion site44.  Although the authors had not themselves seen the cases, 
they had heard of two severe injuries in other parts of the USA.  The first was 
of wrist drop and atrophy of the hand muscles.  The second was such a 
severe injury that amputation of the arm was necessary.  A Spanish follow up 
study described transient paraesthesiae in the hands of three women in a 
series of 372 removals, but the exact distribution of sensory disturbance in 
their hands was not specified45. 
 
 
 Medial cutaneous nerve of the forearm  
In 2001, a case of a neuropathy occurring after removal of Norplant  was 
reported46. In 2006, a further case of nerve damage relating to removal of 
Implanon  was reported from Austria47. The nerve was partially severed 
and needed microsurgical repair. The authors of both reports commented 
on the vulnerability of the site advised by the company with respect to the 
nerves and vessels. 
 
 
 
 
 
 
 
 
 
 
 
 
 Median nerve 
In 2006, two cases of sensory disturbance, possibly in the distribution of the 
median nerve during or immediately after removal of Implanon , were 
reported48. Both women were of slim build. It was thought that the adverse 
effect was merely from the local anaesthetic and so was transient. But the 
author emphasised how it was somewhat perverse to choose an insertion site 
so close to neurovascular structures.  
 
 
 
 
 
 
 
 
 
 
Legal case 1    A GP tried to remove an impalpable Implanon  sited in an area 
previously used for Norplant . At a second unsuccessful attempt at removal of 
the implant, the medial cutaneous nerve of the forearm was damaged. The 
claimant subsequently needed neurolysis (division of perineural adhesions) by 
an upper limb surgeon; the implant was not found at this operation. The 
claimant’s residual neuropraxia was slow to improve. The implant was located 
and removed three years later when the claimant wanted to conceive. 
Legal case 2    A GP failed to remove an Implanon . A local gynaecologist 
later also failed to remove Implanon . A third unsuccessful removal attempt 
was made by a gynaecologist in a tertiary hospital under general anaesthesia. 
During the last operation the median nerve was damaged. The claimant 
subsequently needed neurolysis. The implant was not found. 
  
 Ulnar nerve 
In 1998 two cases of ulnar nerve injury were described with Norplant . The 
first was in a US soldier serving in Germany49. At operation, the nerve was 
intact but had  an “hour-glass” constriction.  Neurolysis was performed two 
months after the injury.  There was residual neurological deficit six months 
postoperatively.  In the second case, Norplant was removed in the USA; the 
implant was situated low down quite near to the elbow50. The woman 
reported sensory symptoms as soon as local anaesthesia was infiltrated into 
the site. Symptoms were continuing to resolve when the woman was seen for 
the last time.  
 
In 2005, two ulnar nerve lesions were reported from France51. Both women 
were of slim build with body mass indices of 18 and 19 respectively. In the 
first case Implanon  had penetrated the perineurium and a microsurgical 
procedure was needed to remove the implant.  In the second case, because 
of persistent sensory disturbance after removal of Implanon , neurolysis was 
needed.  
 
In 2006, a case of ulnar nerve contusion was reported after Norplant  
removal in the UK52. The woman had previously had a difficult removal at the 
same time as a further Norplant  insertion. This time the GP was unable to 
remove any of the capsules. The woman had a subsequent difficult removal 
at a family planning centre and experienced electric shock-like symptoms 
during the procedure but did not mention them at the time.  She then 
developed numbness.  Two days later plastic surgeons explored the wound to 
find the ulnar nerve intact but contused.  The woman made a slow recovery.  
The authors expressed concern about the recommended insertion site.  
 
 
 
Legal case 3    The ulnar nerve was damaged both at insertion and again on 
removal of Implanon  performed by a GP. A complex regional pain syndrome 
ensued and the claimant needed an exploratory operation at which nerve 
repair and neurolysis were performed. 
  
 
 
In the USA, a woman who suffered ulnar nerve injury at the time of 
Norplant  removal by a nurse practitioner was awarded $2.25 million in 
damages53. 
 
 Spontaneous reporting of adverse events in the UK 
The MHRA's online listing of spontaneous reports on etonogestrel implants 
was last updated on 27 May 201054, giving eleven years‟ experience of 
Implanon . Reported adverse reactions suggesting neurological disturbances 
are shown in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1      Adverse reactions reported to the MHRA relating to etonogestrel 
implants  1999 - 2010 
 
 
Implant site paraesthesia 2 
Nerve injury not 
elsewhere        classified 
1 
Median nerve injury 1 
Ulnar nerve injury 5 
Carpal tunnel syndrome 1 
Burning sensation 1 
Paraesthesia 25 
Hypoaesthesia 11 
Neuralgia 4 
Sensory loss 1 
Sensory disturbance 1 
Total 
53 
 
 
 
 Change in insertion site recommended by the manufacturer 
In response to repeated reports of nerve injury, in June 2007 the 
manufacturer revised the Summary of Product Characteristics, deleting 
reference to the biceps/triceps groove.  This revision was accepted by the 
MHRA in August 2007.  A letter dated April 2008 was sent out to all health 
professionals known to be inserting Implanon in July 2008 (personal 
communication, Schering-Plough, 5 June 2009).  The recommended site was 
changed to above the medial epicondyle of the humerus, which is behind the 
groove.  An announcement to this effect was made in the October 2008 
Journal of Family Planning and Reproductive Health Care (page 272).  
 
Although nerve damage is a rare complication of contraceptive implants, it is 
clearly a serious one.  It has been agreed that insertion immediately over the 
biceps/triceps groove is unwise.  
 
 
Discussion 
 
Implant litigation has generally been of two types.  Following the launch of 
Norplant  and Implanon , there was litigation in several countries in relation 
to adverse effects.  It has been shown that class actions tend to exaggerate 
the incidence of a device‟s side effects55. Litigation was not usually successful 
for the claimants, unless the company decided to settle for pragmatic 
business reasons, as in the USA.  However, litigation damaged confidence in 
the products and was responsible for the demise of Norplant  in the UK.   
 
The second type of litigation has been in relation to non-insertion, deep 
insertion and nerve injury. The first two of these can be linked to the design 
of the applicator system, so that it should prove possible to increase safety by 
design improvement15. The potential for reducing harm by training or re-
training is probably limited15. The harm caused by nerve damage is potentially 
the most severe. It is tragic when a healthy young woman suffers long-term 
and in some cases permanent injury through using a method of 
contraception. It is important that efforts are made to learn from legal cases 
and to improve the safety of this highly effective long-acting reversible 
contraceptive method. 
 
It is important to palpate the arm after insertion and to record in the notes 
that this has been done. In some legal cases, clinicians have palpated the 
insertion site and convinced themselves they could feel the implant. They 
have asked the client to palpate the insertion site and, because of never 
having felt an implant before and possibly some local swelling, clients though 
not convinced may tend to agree anyway. Another check might be for the 
client to be told to have a careful feel when taking the dressing off and to 
report any doubts then. 
 
Deep insertion predisposes to injury to the neurovascular bundle. It has been 
suggested that there should be feedback to the person who did the insertion 
when this occurs and, if there are repeat occurrences, to the inserting 
clinician‟s clinical supervisor35;40.   
 
The other element in nerve injury is the optimal insertion site.  Different 
authors have recommended going anterior or posterior to the biceps/triceps 
groove; there is no evidence that one site is better than the other.  But 
insertion over the groove is unwise and surgically trained authors have 
commented in no uncertain terms on this47;52.  The brachial artery can be 
used as a marker for the neurovascular bundle; if it is palpable, the insertion 
site should be a safe distance away from it.  Clinicians need to change their 
practice and avoid the groove. This should, in most cases, prevent the risk of 
neurovascular injury during difficult removals.   
 
Regional experts themselves need to know their limitations. These experts 
may have surgical experience, but this is usually of a gynaecological nature.  
It has become accepted that regional experts do operations with retractors, 
forceps and dissection.  This may not always be in clients‟ best interests.  
There should be a lower threshold for referral to upper limb surgeons or 
interventional radiologists, preferably those who have developed a special 
interest in implants and their localisation.  It has been suggested that some 
deep implants that are beyond their lifespan may be best left in situ rather 
than performing a procedure predicted to be risky29. 
 
 
 
 
Recommendations for safe clinical practice 
 
In conclusion, reflecting on cases that have been reported in the literature or 
that have been subject to litigation, the following recommendations (Boxes 1 
and 2) are made in relation to insertion and removal of contraceptive 
implants.  It can reasonably be assumed that the current improvements in the 
design of the product will reduce the risks of both non-insertion and deep 
insertion. However, it may not be possible to eliminate them; deep insertion 
has been seen in preliminary experience with Nexplanon 12. 
 
At the time of publication of this article the new product, Nexplanon , will 
have been launched. These recommendations are aimed at improving future 
practice. 
 
 
 
 
 
Box 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box 2 
 
 
INSERTION 
 
 Avoid the biceps/triceps groove  
 Palpate for the brachial artery and, if palpable, keep at least 
1cm away from it 
 Once the skin is punctured by the needle tip, advance the 
needle parallel to the skin surface, keeping superficial by lifting 
the skin with the tip of the needle 
 Palpate the inserted implant through the skin and ensure that 
the woman does so too   
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Figure 1 
 
Replicate right hand side of Figure 1 in Bragg TWH et al. Implantable 
contraceptive devices: primum non nocere JFPRHC 2006; 32: 190 -192 with 
permission.   
REMOVAL 
 
 Palpate the rod and make an assessment of the likely ease of 
removal 
 Always work within your own competence (don‟t just „have a 
go‟). Refer to a more experienced clinician if necessary   
 Palpate for the brachial artery 
 Do not attempt removal if the rod is close to the brachial artery 
 If there is any indication of sensory disturbance, abandon the 
procedure 
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